Asia
The financing was led by Zhonguancun Development Group and Shanghai Creation Investment Management.
The company sold the stake to Sapphire I Holdings at an undisclosed price.
Creat Group will attempt to restructure its $1.5M offer to acquire Biotest after U.S. regulators nixed the deal.
Ark will be responsible for preclinical and clinical development of the molecule.
Teva continues to be battered by its massive debt load and struggling pipeline.
The PE firm made the investment just three years ago.
The FDA issued warning letters to Lupin for two of its manufacturing facilities in Goa and Pithampur, Indore.
Takeda inked a collaboration deal to develop and commercialize Portal’s needle-free drug delivery device for use with some of Takeda’s biologic medicines.
The new Ethicon factory has attracted a total investment of $180 million.
PRESS RELEASES